GLP1R and hydrops fetalis: Conversely, the LEADER trial (GLP1-ra: liraglutide), PIONEER 6 trial (GLP1-ra: oral semaglutide) and EXSCEL trial (GLP1-ra: exenatide) described a significant reduction in all-cause mortality and a non-statistically significant reduction in hospitalisation for HF in the GLP1-ra group compared with placebo [28, 35, 36].